BEVACIZUMAB
APHP241020
Phase 2 small_molecule active
Quick answer
BEVACIZUMAB for Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection. is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active